Biocrates Raises €5 Million in Venture Financing
Complete the form below to unlock access to ALL audio articles.
Biocrates life sciences has announced the close of a €5 million private equity investment from the German MIG funds.
This investment further strengthens Biocrates’ position in the field of high content analysis and discovery of multiparametric biomarkers for pharmaceutical R&D, and clinical diagnostics.
"Biocrates has a successful track record of applying its innovative technology in many areas of pharmaceutical and diagnostic collaborations," said Dr. Armin Graber, CEO of Biocrates.
"Now we will enable laboratories world-wide to utilize high content targeted metabolite analysis for biomarker discovery."
"These funds will allow to realize our commercialization goals of our metabolite analysis platform, application software and consumable-based products, and we are delighted to have the MIG corporations join our current investors."
The MIG corporations raise venture capital to invest preferentially into selected businesses in Germany and Austria. A major criterion for investment is the evaluation of the company for sustainable growth.
A convincing candidate must offer an innovative and promising product pipeline substantiated by entrepreneurial accomplishments of the executive management.
"At Biocrates the international and experienced management team has a long track record of success in a very short time," confirms Michael Motschmann, chairman of MIG’s board of directors.
"Achievement of milestones in research collaborations and promising results from consumable-based prototypes convinced us, that they will bring innovative metabolite analysis products for biomarker discovery to the market."
